Mictamid® for Vets
Mictamid is a soft, water-based, non-particulate hydrogel designed to support urethral coaptation in dogs with urethral sphincter mechanism incompetence. When placed in the urethral wall, it provides predictable bulking and long-term structural support.
How Is It Treated?
Some dogs are initially managed with medication. For dogs who do not respond adequately, or when a more durable structural approach is needed, a minimally invasive injectable hydrogel treatment may be considered.
Mictamid® is a non-particulate, water-based hydrogel composed of 97.5% water and 2.5% polyacrylamide, injected into the urethral wall.
Once placed, the hydrogel integrates with surrounding tissue and forms a stable scaffold that supports urethral coaptation. It allows the exchange of oxygen and nutrients while remaining permanently in place without resorption, migration, or flattening.
This added structural support helps improve urethral closure and reduce or eliminate urine leakage.
SAFE
Bulking agent that achieves therapeutic effect without chronic inflammation or fibrosis.
Non pharmaceutical, biocompatible hydrogel comprised of 97.5% water and 2.5% cross linked polyacrylamide.
Homogenous, inert, non-degradable, non-migratory, and non-toxic.
DURABLE
Maintains volume long term.
Designed for multi-year continence improvement.
2.5% iPAAG permanently integrates into tissue and is not absorbed like other bulking products.
EFFICACIOUS
Strong veterinary clinical outcomes across treated species.
Demonstrated improvement in continence outcomes in dogs with USMI based on veterinary clinical experience and early adopter data.
Non-particulate, non-resorbable hydrogel designed for durable tissue bulking.
Early Clinical Experience in Canine USMI
Early evaluations demonstrate consistent improvements when correct volume andplacement are achieved.
- Majority of treated dogs reached full continence.
- Remaining dogs demonstrated meaningful improvement.
- Consistent coaptation achieved with proper submucosal depth.
- Low incidence of transient adverse events.
JD Foster, VMD, MS, DACVIM (SAIM), DACVCP, DACVNU
ACVNU Founding Member, Nephrologist-Urologist
“Mictamid represents a significant advancement in the management of USMI. When the hydrogel is delivered precisely into the submucosal plane, it provides a safe and highly effective means of achieving urethral coaptation to correct urinary incontinence.”
Standardized Injection Technique
- Mictamid® is injected into the urethral submucosa under cystoscopic guidance.
- A standardized two-series injection technique supports circumferential coaptation and reproducible results.
- Four injections per series at 5, 7, 2, and 10 o’clock.
- Foundational injection series approximately 2 cm from the bladder neck.
- Reinforcing injection series approximately 2 cm distal to the foundational series.
- Total target volume equals 5 mL.
- Administered through a novel, proprietary delivery system designed specifically for canine urethral anatomy.
Key Advantages for Your Practice
- Fast and cost-effective procedure performed under sedation.
- Minimally invasive outpatient procedure.
- Reduces or eliminates the need for lifelong medication.
- Durable soft tissue bulking.
- Proprietary delivery system designed for canine anatomy.
Training and Support
- Wet labs in office.
- Procedural videos coming soon.
- Peer-to-peer case observation; live or virtual.
Discover how Mictamid supports durable urethral coaptation in dogs with USMI
Give your patients a long-term structural option for managing urinary incontinence.